- Home
- BRLT vs TVRD Comparison
BRLT vs TVRD Comparison
Compare BRLT & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRLT | TVRD |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.6M | 34.1M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | BRLT | TVRD |
|---|---|---|
| Price | $1.54 | $3.79 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $2.00 | ★ $51.67 |
| AVG Volume (30 Days) | ★ 74.0K | 52.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $422,161,000.00 | N/A |
| Revenue This Year | $5.92 | N/A |
| Revenue Next Year | $4.06 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.26 | $3.50 |
| 52 Week High | $3.10 | $43.65 |
Technical Indicators
Market Signals| Indicator | BRLT | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 47.43 | 39.92 |
| Support Level | $1.34 | N/A |
| Resistance Level | $1.65 | $4.52 |
| Average True Range (ATR) | 0.10 | 0.29 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 73.68 | 21.28 |
Price Performance
Historical ComparisonAbout BRLT Brilliant Earth Group Inc.
Brilliant Earth Group Inc is a digitally native omnichannel jewelry company. The company designs, procures and sells ethically-sourced diamonds, gemstones and jewelry online and through showrooms. The sales of the company consist of revenue from diamond, gemstone, and jewelry retail sales. The company sells its products in the U.S. and other international countries, of which a majority of revenue is derived from the U.S.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.